nyxol
Ocuphire’s pupil dilation treatment shows promising Phase III trial results
March 15, 2021Sales and Marketing Ocuphire, eye treatment, nyxol
Ocuphire Pharma’s Nyxol treatment for pharmacologically-induced pupil dilation (mydriasis) has met its primary and secondary endpoints in its Phase III …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
